Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

(2020) Kris V. Kowdley et al.   JOURNAL OF HEPATOLOGY

Randomised clinical trial: Significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea

(2020) Michael Camilleri et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

(2020) Stefano Fiorucci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Structural basis for DNA recognition by FOXC2

(2019) Xiaojuan Chen et al.   NUCLEIC ACIDS RESEARCH

Molecular tuning of farnesoid X receptor partial agonism

(2019) Daniel Merk et al.   Nature Communications

Structural basis of binding of homodimers of the nuclear receptor NR4A2 to selective Nur-responsive DNA elements

(2019) Longying Jiang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural basis of NR4A1 bound to the human pituitary proopiomelanocortin gene promoter

(2019) Longying Jiang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

(2019) Marcos Pedrosa et al.   Contemporary Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers

(2019) Michael K. Badman et al.   Clinical Pharmacology in Drug Development

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

(2018) Kris V. Kowdley et al.   HEPATOLOGY

LY2874455 potently inhibits FGFR gatekeeper mutant and overcomes mutation-based resistance

(2018) Daichao Wu et al.   CHEMICAL COMMUNICATIONS

The nuclear receptor superfamily: A structural perspective

(2018) Emily R. Weikum et al.   PROTEIN SCIENCE

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

PyMOL mControl: Manipulating molecular visualization with mobile devices

(2016) Wendy W. T. Lam et al.   BIOCHEMISTRY AND MOLECULAR BIOLOGY EDUCATION

Obeticholic Acid: First Global Approval

(2016) A. Markham et al.   DRUGS

Obeticholic acid for the treatment of primary biliary cholangitis

(2016) Ahmad H. Ali et al.   EXPERT OPINION ON PHARMACOTHERAPY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis

(2016) Natalia Gomez-Ospina et al.   Nature Communications

FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease

(2015) Rotonya M. Carr et al.   Current Atherosclerosis Reports

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Bile acids: emerging role in management of liver diseases

(2015) Amon Asgharpour et al.   Hepatology International

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Bile acid receptors as targets for drug development

(2013) Frank G. Schaap et al.   Nature Reviews Gastroenterology & Hepatology

The Phenix software for automated determination of macromolecular structures

(2011) Paul D. Adams et al.   METHODS

Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064

(2008) Adwoa Akwabi-Ameyaw et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

FXR: a metabolic regulator and cell protector

(2008) Yan-Dong Wang et al.   CELL RESEARCH